Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Cappuzzo

Showing results (181-190 of 275) with videos related to

Pageof 28
Sort By:
BJU International|August 30, 2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failureHielke J Meulenbeld, Jean P Bleuse, Elio M Vinci, et al.
Future Oncology (London, England)|March 22, 2023
Combi-TED: a new trial testing Tedopi<sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first lineLorenza Landi, Angelo Delmonte, Andrea Bonetti, et al.
Lung Cancer (Amsterdam, Netherlands)|October 16, 2007
Lung cancer screening with spiral CT: baseline results of the randomized DANTE trialMaurizio Infante, Fabio Romano Lutman, Silvio Cavuto, et al.
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.
Cancers|June 24, 2022
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant SettingIrene Terrenato, Cristiana Ercolani, Anna Di Benedetto, et al.
Oncology Reports|July 5, 2016
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single centerRiccardo Giannini, Cristiana Lupi, Elisa Sensi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsFederico Cappuzzo, Antonio Marchetti, Margaret Skokan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinomaFilippo Tommaso Gallina, Daniele Marinelli, Riccardo Tajè, et al.
Pageof 28

Showing results (181-190 of 275) with videos related to

Sort By:
Pageof 28
BJU International|August 30, 2012
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failureHielke J Meulenbeld, Jean P Bleuse, Elio M Vinci, et al.
Future Oncology (London, England)|March 22, 2023
Combi-TED: a new trial testing Tedopi<sup>®</sup> with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first lineLorenza Landi, Angelo Delmonte, Andrea Bonetti, et al.
Lung Cancer (Amsterdam, Netherlands)|October 16, 2007
Lung cancer screening with spiral CT: baseline results of the randomized DANTE trialMaurizio Infante, Fabio Romano Lutman, Silvio Cavuto, et al.
Neoplasia (New York, N.Y.)|October 2, 2009
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clonesAntonio Marchetti, Michele Milella, Lara Felicioni, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 23, 2023
Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4)Robin Cornelissen, Arsela Prelaj, Sophie Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014Benjamin J Solomon, Federico Cappuzzo, Enriqueta Felip, et al.
Cancers|June 24, 2022
A Real-World Systematic Analysis of Driver Mutations' Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant SettingIrene Terrenato, Cristiana Ercolani, Anna Di Benedetto, et al.
Oncology Reports|July 5, 2016
EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single centerRiccardo Giannini, Cristiana Lupi, Elisa Sensi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patientsFederico Cappuzzo, Antonio Marchetti, Margaret Skokan, et al.
European Journal of Cancer (Oxford, England : 1990)|July 18, 2025
TP53 co-mutations increase risk of recurrence in EGFR-mutated stage I lung adenocarcinomaFilippo Tommaso Gallina, Daniele Marinelli, Riccardo Tajè, et al.
Pageof 28